tirzepatide

Product

Last mentioned: 2d ago

Timeline

  1. Impurity Warning

    Lilly issues formal warning after testing reveals impurities in compounded samples.

  2. Compounding Surge

    Shortage status triggers Section 503B exemptions, allowing pharmacies to mass-produce compounded versions.

  3. Zepbound Approval

    Tirzepatide approved for chronic weight management, exacerbating supply shortages.

  4. Mounjaro FDA Approval

    FDA approves tirzepatide for type 2 diabetes, leading to immediate high demand.

Stories mentioning tirzepatide 1

Regulation Bearish

Lilly Flags Impurities in Compounded GLP-1s, Escalating Regulatory Battle

Eli Lilly has issued a formal warning regarding discovered impurities in compounded versions of its blockbuster weight-loss medication, tirzepatide. This development marks a significant escalation in the ongoing regulatory and legal conflict between pharmaceutical giants and the compounding industry over safety standards and patent enforcement.

23 sources